First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control

Publisher： Karger

E-ISSN： 1423-0232|90|2|88-96

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.2, 2016-0, pp. : 88-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 8, 2015-08 ,pp. : 1081-1087

John Wiley & Sons Inc

Access to resources Recommend Favorite

S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 5, 2013-04 ,pp. : 305-310

Karger

Access to resources Recommend Favorite

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

By  

Oncology, Vol. 92, Iss. 4, 2017-01 ,pp. : 221-228

Karger

Access to resources Recommend Favorite

First-Line High-Dose Chemotherapy for ’Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors

By  

Oncology Research and Treatment, Vol. 21, Iss. 2, 1998-06 ,pp. : 23-25

Karger

Access to resources Recommend Favorite

Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 363-369

Karger

Access to resources Recommend Favorite